Mineralys’ MLS-101 is being analysed in a Phase II Target-HTN trial in patients with uncontrolled hypertension. Credit: John Campbell / Flickr (Creative Commons).

Mineralys Therapeutics has raised $118m in a Series B funding round to advance the development of MLS-101, a new targeted treatment for hypertension.

RA Capital Management and Andera Partners led the financing round with participation from new investors RTW Investments, Rock Springs Capital, SR One Capital Management and Sectoral Asset Management among others.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Current investors, including Catalys Pacific, HBM Healthcare Investments, Samsara BioCapital and Adams Street Partners also took part in the financing. 

Andera partner Olivier Litzka and RA Capital Management partner Derek DiRocco will join the board of directors of Mineralys as part of the financing.

An inhibitor of aldosterone synthase, MLS-101 is presently being analysed in a Phase II Target-HTN clinical trial in patients with uncontrolled hypertension. 

See Also:

The company expects to report top-line data from this trial later this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Licenced from Mitsubishi Tanabe Pharma, MLS-101 is claimed to lower plasma aldosterone levels by hindering the CYP11B2 pathway linked to aldosterone synthesis, without the unexpected effects of inhibiting the mineralocorticoid receptor.

Abnormally raised aldosterone is an underlying cause of hypertension rampant in a substantial portion of patients.

The therapy was analysed in a Phase I programme in healthy subjects that established the aldosterone lowering effects of MLS-101 and showed a safe and tolerable clinical profile. 

In addition to hypertension, MLS-101 may be beneficial for end-stage renal disease, cardiac heart failure and cardiac mortality.

Mineralys Therapeutics CEO Jon Congleton said: “MLS-101 has the potential to be a paradigm-shifting treatment by normalizing plasma aldosterone levels, selectively, without the untoward effects of blocking the mineralocorticoid receptor. 

“This financing will allow us to further our clinical programme to unlock the value of MLS-101.”